Banco BTG Pactual S.A. Takes Position in Natera, Inc. (NASDAQ:NTRA)

Banco BTG Pactual S.A. acquired a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,644 shares of the medical research company's stock, valued at approximately $1,870,000.

Other large investors have also bought and sold shares of the company. Blue Trust Inc. boosted its stake in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc increased its stake in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after purchasing an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. boosted its holdings in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after buying an additional 59 shares during the period. Finally, True Wealth Design LLC purchased a new position in shares of Natera in the third quarter worth approximately $57,000. Institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on NTRA. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Royal Bank of Canada began coverage on Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target on the stock. BTIG Research restated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Robert W. Baird upped their target price on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Finally, StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $178.12.

Remove Ads

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 1,026 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $146.04, for a total transaction of $149,837.04. Following the transaction, the insider now directly owns 144,782 shares in the company, valued at $21,143,963.28. The trade was a 0.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Michael Burkes Brophy sold 25,931 shares of Natera stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07. Following the sale, the chief financial officer now directly owns 109,665 shares in the company, valued at $18,091,435.05. The trade was a 19.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 306,797 shares of company stock worth $48,940,883 over the last three months. 7.60% of the stock is currently owned by insiders.

Natera Stock Down 2.9 %

Shares of NASDAQ NTRA traded down $4.36 during mid-day trading on Friday, reaching $143.94. 1,258,459 shares of the company traded hands, compared to its average volume of 1,364,577. The stock has a market cap of $19.46 billion, a PE ratio of -81.78 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company's fifty day moving average is $159.60 and its two-hundred day moving average is $150.94. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. On average, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.